Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

The study has a randomized, double-blind, placebo-controlled parallel group design.
Approximately 198 subjects will be randomized to 5 treatment groups. Each subject will
participate in the study for approximately 23 weeks including a 30 day screening period, 15
week double blind treatment period, and an approximately 28 day follow-up period.

Inclusion Criteria:

- Females of non-childbearing potential and/or male subjects between the ages of 40 and
85 years, inclusive.

- Clinical diagnosis of Parkinson's disease.

- Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Exclusion Criteria:

- Female of childbearing potential

- History or presence of atypical Parkinsonian syndrome.

- History of surgical intervention for Parkinson's disease.

- Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

- Any condition possibly affecting drug absorption.

- Participation in other studies involving investigational drug(s), or treatment with
any investigational drug within 30 days.